Abstract:Background: Sclerostin is an inhibitor of the Wnt/b-catenin pathway, which regulates bone formation, and can be expressed in vascular smooth muscle cells (VSMCs). Type 2 diabetes (T2D) is associated with an increased risk of cardiovascular disease (CVD) and increased serum and tissue expression of sclerostin. However, whether the role of sclerostin is detrimental or protective in the development of CVD is unknown. Therefore, our aims are to determine the level of sclerostin in T2D patients with/without CVD and in controls, both at serum and vascular tissue, and to analyze the role of sclerostin in VSMCs under calcified environments. Methods: Cross-sectional study including 121 controls and 139 T2D patients with/without CVD (48/91). Sclerostin levels in serum were determined by ELISA, and sclerostin expression was analyzed by RT-qPCR and immunohistochemistry in calcified and non-calcified artery of lower limb from T2D patients (n = 7) and controls (n = 3). In vitro experiments were performed in VSMCs (mock and sclerostin overexpression) under calcifying conditions analyzing the sclerostin function by determination of calcium and phosphate concentrations, and quantification of calcium deposits by Alizarin Red. Proliferation and apoptosis were analyzed by MTT assay and flow cytometry, respectively. The regulation of the expression of genes involved in bone metabolism was determined by RT-qPCR. Results: A significant increase in serum sclerostin levels in T2D patients with CVD compared to T2D patients without CVD and controls (p < 0.001) was observed. Moreover, higher circulating sclerostin levels were independently associated with CVD in T2D patients. Increased sclerostin expression was observed in calcified arteries of T2D patients compared to non-calcified arteries of controls (p = 0.003). In vitro experiments using VSMCs under calcified conditions, revealed that sclerostin overexpression reduced intracellular calcium (p = 0.001), calcium deposits (p < 0.001), cell proliferation (p < 0.001) and promoted cell survival (p = 0.015). Furthermore, sclerostin overexpression exhibited up-regulation of ALPL (p = 0.009), RUNX2 (p = 0.001) and COX2 (p = 0.003) and down-regulation of inflammatory genes, such as, IL1β (p = 0.005), IL6 (p = 0.001) and IL8 (p = 0.003). Conclusions: Sclerostin could play a protective role in the development of atherosclerosis in T2D patients by reducing calcium deposits, decreasing proliferation and inflammation, and promoting cell survival in VSMCs under calcifying conditions. Therefore, considering the bone-vascular axis, treatment with anti-sclerostin for bone disease should be used with caution.

Wnt signaling pathway and sclerostin in the development of atherosclerosis and vascular calcification

Sclerostin Protects Against Vascular Calcification Development in Mice

Cardioprotective function of sclerostin by reducing calcium deposition, proliferation, and apoptosis in human vascular smooth muscle cells

Sclerostin and Cardiovascular Disease

Significance of the Wnt signaling pathway in coronary artery atherosclerosis

Wnt Signaling in Vascular Calcification

Sclerostin is Involved in Osteogenic Transdifferentiation of Vascular Smooth Muscle Cells in Chronic Kidney Disease-Associated Vascular Calcification with Non-Canonical Wnt Signaling.

Sclerostin and skeletal health

Wnt signaling contributes to vascular calcification by induction of matrix metalloproteinases

Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness

Arterial Stiffness: A Focus on Vascular Calcification and Its Link to Bone Mineralization.

Drug discovery of sclerostin inhibitors

The potential use of antisclerostin therapy in chronic kidney disease-mineral and bone disorder

Cardiovascular Safety and Sclerostin Inhibition

Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation

Sclerostin blockade inhibits bone resorption through PDGF receptor signaling in osteoblast lineage cells

Effects of sclerostin on lipopolysaccharide-induced inflammatory phenotype in human odontoblasts and dental pulp cells.

Lifelong genetically lowered sclerostin and risk of cardiovascular disease.

Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a Genome-Wide Association Meta-Analysis Followed by Mendelian Randomization

Τhe story of sclerostin inhibition: the past, the present, and the future